Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast-2030
(Albany, US) DelveInsight launched a new report on Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report1. Acute Myeloid Leukemia accounts for less than 3% of all cancers, and 25% of all leukaemia in adults.2. Worldwide, Acute Myeloid Leukemia incidence was reported to be highest in the US, Australia, and Western Europe.3. From 2000 to 2003, the US incidence rate in people age in less than 65 years was only 1.8 per 100,000 persons, whereas Acute Myeloid Leukemia incidence rate in people age 65 years was 17 per 100,000 persons.
Key benefits of the report
1. Acute Myeloid Leukemia market report covers a descriptive overview and comprehensive insight of the Acute Myeloid Leukemia Epidemiology and Acute Myeloid Leukemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Acute Myeloid Leukemia market report provides insights on the current and emerging therapies.3. Acute Myeloid Leukemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Acute Myeloid Leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market.
Request for sample pages
“Acute Myeloid Leukemia is one of the most common types of leukaemia in adults, and even being rare, it is the leading cause of leukaemia-related deaths. It is found to be slightly more common among men as compared to women.”
Acute Myeloid Leukemia is the most common leukaemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, Acute Myeloid Leukemia treatment usually needs to start as quickly as possible, as the disease progresses very quickly.
Acute Myeloid Leukemia treatment depends on age, risk factors, and the sub-types of the disease. The main aim of treatment is to cure it and to achieve remission of leukaemia cells. Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are divided into two phases, i.e. remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine, either given alone or in combinatorial doses. Consolidation therapy is given in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone. Age, performance status, prognostic indicators were the major resistance factors to chemotherapy effectiveness. While the initial therapy for Acute Myeloid Leukemia treatment is relatively standardized, the high incidence of refractory/relapsed disease remains a significant challenge. In resistant cases, stem cell transplantation (with autologous or allogeneic) is the only available Acute Myeloid Leukemia treatment option.
The huge breakthrough has been seen in Acute Myeloid Leukemia treatment with greater availability of new treatments in a couple of years, often targeting specific abnormalities. The molecules are being developed as FLT3 Inhibitors, IDH Inhibitors, targeting key cellular pathways such as BCL-2 specific inhibitors and others by targeting recurrent driver mutations of AML. These are used in the case when chemo no longer responds and can ideally tailor to each patient’s disease with a subset-specific. FLT3 Inhibitors such as Midostaurin and Gilteritinib; IDH Inhibitors such as Enasidenib and Ivosidenib; and Hedgehog pathway inhibitor, such as Glasdegib; BCL-2 inhibitor such as Venetoclax have recently entered the Acute Myeloid Leukemia market as promising targeted therapies with specific genetic mutations.
The launch of the emerging therapies is expected to significantly impact the Acute Myeloid Leukemia treatment scenario in the upcoming years:-Drugs covered1. Iomab-B CD45 and Actimab-A CD332. Ficlatuzumab3. Devimistat4. BST-2365. Quizartinib6. Bemcentinib7. Pracinostat8. GuadecitabineAnd many others
The key players in Acute Myeloid Leukemia market are:1. Actinium Pharmaceuticals2. AVEO Oncology3. Biodesix4. Daiichi Sankyo5. BioSight6. Helsinn Healthcare7. Rafael Pharmaceuticals8. Otsuka Pharmaceutical9. Cyclacel PharmaceuticalsAnd many others
Table of contents1. Report Introduction2. Acute Myeloid Leukemia Market Overview at a Glance3. Acute Myeloid Leukemia Disease Background and Overview4. Acute Myeloid Leukemia Epidemiology and Patient Population4.1. Assumptions and Caveats4.2. 7MM Incident cases of Acute Myeloid Leukemia (2017–2030)4.3. Age-Specific cases of Acute Myeloid Leukemia (2017–2030)4.4. Relapsed/Refractory Cases of Acute Myeloid Leukemia (2017–2030)4.5. Diagnosed and Treatable cases of Acute Myeloid Leukemia (2017–2030)4.6. Acute Myeloid Leukemia Country-Wise Epidemiology4.7. United States4.8. EU-54.9. Assumptions and Rationale4.10. Germany4.11. France4.12. Italy4.13. Spain4.14. United Kingdom4.15. Japan5. Acute Myeloid Leukemia Treatments & Medical Practices6. Unmet needs7. Acute Myeloid Leukemia Marketed Therapies7.1. Rydapt (Midostaurin): Novartis7.2. Mylotarg (Gemtuzumab ozocgamicin): Pfizer7.3. XOSPATA (Gilteritinib): Astellas Pharma8. Acute Myeloid Leukemia Emerging Therapies9. Key Cross Competition9.1. Quizartinib: Daiichi Sankyo9.2. Iomab-B CD45: Actinium Pharmaceuticals9.3. CPI-613: Rafael Pharmaceuticals9.4. Bemcentinib: BerGenBio10. Acute Myeloid Leukemia Market Size11. 7MM Acute Myeloid Leukemia: Country-Wise Market Analysis12. United States Market Size13. Germany Market Size14. France Market Size15. United Kingdom Market Size16. Spain Market Size17. Italy Market Size18. Japan Market Size19. Market Drivers20. Market Barriers21. Appendix22. Acute Myeloid Leukemia Report Methodology23. DelveInsight Capabilities24. Disclaimer25. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:Shruti Thakur[email protected]+919650213330SOURCE DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/